Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
about
New developments in atherosclerosis: clinical potential of PCSK9 inhibitionProfile of evolocumab and its potential in the treatment of hyperlipidemiaRetargeting the management of hypercholesterolemia - focus on evolocumabSafety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.Managing the lipid profile of coronary heart disease patients.Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.
P2860
Q26783407-B92ACA2E-7673-4F77-B5CC-F2C867C2F9E4Q27004235-A4A70CAD-365F-4F30-A71E-9AED14D2213AQ28077289-04F63B56-D960-4285-9663-284CD39CD2E2Q30833167-CE4D425B-34CD-4B56-9A68-B026D9DB2919Q37688760-68A45B46-2F8E-4BAA-8795-B905B8C1058DQ38748787-6383464C-FABC-4A5A-B661-DC9F4E4869A8Q38934909-3C9E53CF-1A58-4DC7-B46D-A12537483DF9Q46627262-8108BDB0-38C0-4710-B77A-5A5771DCC70BQ47844045-A3222C8A-29BB-4F93-B600-1C317957FD43Q48274225-8F0663CF-DAAC-4DFA-9379-18F662EB8737
P2860
Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Efficacy and safety profile of ...... e available clinical evidence.
@en
type
label
Efficacy and safety profile of ...... e available clinical evidence.
@en
prefLabel
Efficacy and safety profile of ...... e available clinical evidence.
@en
P2860
P1476
Efficacy and safety profile of ...... he available clinical evidence
@en
P2093
Elisa Tartagni
Sibel Ertek
P2860
P304
P356
10.1517/14712598.2014.902929
P407
P577
2014-03-24T00:00:00Z